Biohaven (BHVN) Return on Capital Employed (2022 - 2026)
Biohaven (BHVN) reported Return on Capital Employed of 160.81% for Q1 2026, up 8677.0% on a YoY basis from 1.83% in Q1 2025, and up 32.18% sequentially from 237.12% in Q4 2025.
Biohaven (BHVN) Return on Capital Employed (2022 - 2026) Analysis & Trends
Biohaven (BHVN) has 5 years of Return on Capital Employed data on file, last reported at 160.81% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 8677.0% year-over-year to 160.81%; the trailing twelve-month figure through Mar 2026 stood at 160.81% (up 8677.0% YoY), and the FY2025 full-year result was 178.6%, up 3731.0% from the prior year.
- Return on Capital Employed climbed to 160.81% in Q1 2026, from 237.12% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 95.38% in Q2 2023 to a low of 247.57% in Q1 2025.
- A 5-year average of 178.54% and a median of 197.33% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 13148 bps in 2024 and surged 8677 bps in 2026, its largest moves.
- Tracing BHVN's Return on Capital Employed over 5 years: stood at 183.98% in 2022, then soared by 40 bps to 111.08% in 2023, then plunged by 95 bps to 216.63% in 2024, then fell by 9 bps to 237.12% in 2025, then jumped by 32 bps to 160.81% in 2026.
- Business Quant data shows BHVN's Return on Capital Employed at 160.81% in Q1 2026, 237.12% in Q4 2025, and 216.11% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Biohaven | 2.16 Bn | 1.81 Bn | - | -160.81% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -160.81% |
| Dec 31, 2025 | -237.12% |
| Sep 30, 2025 | -216.11% |
| Jun 30, 2025 | -210.69% |
| Mar 31, 2025 | -247.57% |
| Dec 31, 2024 | -216.63% |
| Sep 30, 2024 | -215.30% |
| Jun 30, 2024 | -226.86% |
| Mar 31, 2024 | -142.77% |
| Dec 31, 2023 | -111.08% |
| Sep 30, 2023 | -129.59% |
| Jun 30, 2023 | -95.38% |
| Mar 31, 2023 | -105.66% |
| Dec 31, 2022 | -183.98% |